Hennion & Walsh Asset Management, Inc. Mesoblast LTD Transaction History

Hennion & Walsh Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$2.94 - $4.18 $17,010 - $24,185	-5,786 Reduced 3.31%	168,915 $556,000
Q4 2022 Jan 12, 2023	SELL	$2.73 - $3.7 $477,335 - $646,937	-174,848 Reduced 50.02%	174,701 $508,000
Q3 2022 Nov 14, 2022	SELL	$0.48 - $3.48 $6,354 - $46,068	-13,238 Reduced 3.65%	349,549 $890,000
Q2 2022 Jul 19, 2022	SELL	$2.22 - $4.54 $26,566 - $54,330	-11,967 Reduced 3.19%	362,787 $805,000
Q1 2022 Apr 26, 2022	SELL	$3.58 - $4.98 $16,578 - $23,062	-4,631 Reduced 1.22%	374,754 $1.58 Million
Q4 2021 Feb 14, 2022	SELL	$4.17 - $7.09 $45,961 - $78,145	-11,022 Reduced 2.82%	379,385 $1.82 Million
Q3 2021 Nov 12, 2021	BUY	$5.87 - $7.85 $257,886 - $344,874	43,933 Added 12.68%	390,407 $2.35 Million
Q2 2021 Aug 13, 2021	BUY	$6.69 - $9.0 $866,950 - $1.17 Million	129,589 Added 59.75%	346,474 $2.59 Million
Q1 2021 May 17, 2021	BUY	$8.26 - $11.4 $1.79 Million - $2.47 Million	216,885 New	216,885 $1.79 Million

151K

Ticker MESO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 147,316,000
Market Cap $2.51B
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.